FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W85658816> ?p ?o ?g. }

• W85658816 abstract "Malignant pleural mesothelioma represents a rare disease, for which chemotherapy actually remains unsatisfactory. From August 1998 to November 2001, 28 chemo-radio-immunonaive patients were consecutively enrolled in the trial: 22/6 males/females; median age 63 years (range, 45-79); median ECOG PS 1 (range, 0-2). They were treated with epirubicin (100 mg/m2 iv on day 1) plus gemcitabine (1000 mg/m2 iv on days 1 and 8) every 4 weeks for 6 cycles. Patients who responded to chemotherapy (n = 6) were subsequently treated with interleukin-2 (4,500,000 IU) subcutaneously every other day, until progression. A total of 124 epirubicin-gemcitabine cycles were administered (median, 6/patient; range, 2-6). Twenty-six patients were evaluated for toxicity. According to WHO criteria, we observed grade III-IV hematological and gastrointestinal toxicity respectively in 3 patients (11%) and 1 patient (3%). No red cell transfusions were required and no toxic deaths occurred. Two patients (8%) could not be evaluated for response (no therapy performed). According to WHO criteria, the final responses were: partial in 4 patients (14%), stable disease in 19 patients (69%), and progression in 3 patients (10%). In 26 patients, the median survival was 55 weeks (range, 7-222) and median time to progression 30 weeks (range, 4-156). At the time of this writing, no patient is alive. The 1-year survival was 32%, 2-year survival 11%, and 4% at 3 and 4 years. All patients were at stage III, and time to progression was 58 weeks and survival 63.5 weeks, without any toxicity. This multi-center phase II clinical trial showed that epirubicin plus gemcitabine, as a first-line treatment in malignant pleural mesothelioma, has promising activity with a good tolerability profile and symptom palliation. The role of interleukin-2 in maintenance therapy for malignant pleural mesothelioma is encouraging and requires further study." @default.
• W85658816 created "2016-06-24" @default.
• W85658816 creator A5012596359 @default.
• W85658816 creator A5016612899 @default.
• W85658816 creator A5028186076 @default.
• W85658816 creator A5033544525 @default.
• W85658816 creator A5039478541 @default.
• W85658816 creator A5043204599 @default.
• W85658816 creator A5062219316 @default.
• W85658816 creator A5066126386 @default.
• W85658816 creator A5082025328 @default.
• W85658816 creator A5085341141 @default.
• W85658816 creator A5090055323 @default.
• W85658816 date "2005-01-01" @default.
• W85658816 modified "2023-09-27" @default.
• W85658816 title "Epirubicin and Gemcitabine as First-Line Treatment in Malignant Pleural Mesothelioma" @default.
• W85658816 cites W1948574410 @default.
• W85658816 cites W1972561967 @default.
• W85658816 cites W1977991723 @default.
• W85658816 cites W1997341644 @default.
• W85658816 cites W2008769116 @default.
• W85658816 cites W2022538901 @default.
• W85658816 cites W2049106080 @default.
• W85658816 cites W2096085739 @default.
• W85658816 cites W2102627969 @default.
• W85658816 cites W2122514344 @default.
• W85658816 cites W2125980018 @default.
• W85658816 cites W2127235139 @default.
• W85658816 cites W2142835139 @default.
• W85658816 cites W2167805334 @default.
• W85658816 cites W2317855291 @default.
• W85658816 cites W2410322403 @default.
• W85658816 doi "https://doi.org/10.1177/030089160509100104" @default.
• W85658816 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15849999" @default.
• W85658816 hasPublicationYear "2005" @default.
• W85658816 type Work @default.
• W85658816 sameAs 85658816 @default.
• W85658816 citedByCount "11" @default.
• W85658816 countsByYear W856588162012 @default.
• W85658816 countsByYear W856588162014 @default.
• W85658816 countsByYear W856588162017 @default.
• W85658816 crossrefType "journal-article" @default.
• W85658816 hasAuthorship W85658816A5012596359 @default.
• W85658816 hasAuthorship W85658816A5016612899 @default.
• W85658816 hasAuthorship W85658816A5028186076 @default.
• W85658816 hasAuthorship W85658816A5033544525 @default.
• W85658816 hasAuthorship W85658816A5039478541 @default.
• W85658816 hasAuthorship W85658816A5043204599 @default.
• W85658816 hasAuthorship W85658816A5062219316 @default.
• W85658816 hasAuthorship W85658816A5066126386 @default.
• W85658816 hasAuthorship W85658816A5082025328 @default.
• W85658816 hasAuthorship W85658816A5085341141 @default.
• W85658816 hasAuthorship W85658816A5090055323 @default.
• W85658816 hasConcept C126322002 @default.
• W85658816 hasConcept C141071460 @default.
• W85658816 hasConcept C142724271 @default.
• W85658816 hasConcept C2776694085 @default.
• W85658816 hasConcept C2776755627 @default.
• W85658816 hasConcept C2777407522 @default.
• W85658816 hasConcept C2780258809 @default.
• W85658816 hasConcept C2780835546 @default.
• W85658816 hasConcept C29730261 @default.
• W85658816 hasConcept C71924100 @default.
• W85658816 hasConcept C90924648 @default.
• W85658816 hasConceptScore W85658816C126322002 @default.
• W85658816 hasConceptScore W85658816C141071460 @default.
• W85658816 hasConceptScore W85658816C142724271 @default.
• W85658816 hasConceptScore W85658816C2776694085 @default.
• W85658816 hasConceptScore W85658816C2776755627 @default.
• W85658816 hasConceptScore W85658816C2777407522 @default.
• W85658816 hasConceptScore W85658816C2780258809 @default.
• W85658816 hasConceptScore W85658816C2780835546 @default.
• W85658816 hasConceptScore W85658816C29730261 @default.
• W85658816 hasConceptScore W85658816C71924100 @default.
• W85658816 hasConceptScore W85658816C90924648 @default.
• W85658816 hasLocation W856588161 @default.
• W85658816 hasLocation W856588162 @default.
• W85658816 hasOpenAccess W85658816 @default.
• W85658816 hasPrimaryLocation W856588161 @default.
• W85658816 hasRelatedWork W2005899744 @default.
• W85658816 hasRelatedWork W2124467608 @default.
• W85658816 hasRelatedWork W2339734112 @default.
• W85658816 hasRelatedWork W2376240298 @default.
• W85658816 hasRelatedWork W2383559318 @default.
• W85658816 hasRelatedWork W2406364385 @default.
• W85658816 hasRelatedWork W2589224726 @default.
• W85658816 hasRelatedWork W655539898 @default.
• W85658816 hasRelatedWork W84644448 @default.
• W85658816 hasRelatedWork W2131513168 @default.
• W85658816 isParatext "false" @default.
• W85658816 isRetracted "false" @default.
• W85658816 magId "85658816" @default.
• W85658816 workType "article" @default.